i.c.m (11 -6) Infants with apnea and increased levels of P-endorphin immunoreactivity in the CSF have been successfully treated with the p r e c e p t o r antagonist naloxone i.v. (1) (2) (3) . P-Endorphin is a p-agonist, and may depress the respiratory rate, tidal volume, and heart rate when injected i.c.m. (4) . Furthermore, infants with apnea caused by gastroesophageal refux have increased levels of P-endorphin inimunoreactivity in plasma (5) . After correction of gastroesophageal refluxes in infants with acute life threatening episodes, the plasma P-endorphin levels decreased (6) .
'I'he gastroesophageal reflux may stimulate the laryngeal chelnoreflex and result in apnea, decreased heart rate, and increased blood pressure (7) . In dogs the duration of the laryngeal chemoreflex-induced apnea and the decrease in the heart rate were reduced after treatment with naloxone (8) .
When this reflex was induced in piglets. P-endorphin was released into the CSF, and the levels of P-endorphin immune- (9) . Interestingly, hypoxia does not increase the P-endorphin imrnunoreactivity levels in the C S F (10, 11) .
To investigate the possibility that P-endorphin is involved in the laryngeal chemoreflex-induced apnea, we injected diRerent doses of P-endorphin i.c.rn. in 5-10-d-old piglets and followed their respiratory and cardiovascular patterns. From 0.1 to 1 m g of P-endorphin i.c.m. induced respiratory pauses accompanied by blood pressure increases and reductions in heart rate within 30 min, similar to the respiratory andl cardiovascular pattern seen during the laryngeal chemoreflex. Based on these initial experiments, we found that 0.1 m g of P-endorphin i.c.m. was the lowest effective dose inducing respiratory pauses accompanied by blood pressure increases and reductions in heart rate. We therefore studied the laryngeal chemoreflex in piglets pretreated with 0. 
METHODS
Approval. The experimental protocol was approved by the hospital's ethical committee for animal studies.
Animals. Forty-nine piglets (5-10-d-old; median weight, 2.6 kg; weight range, 1.3-3.9 kg; 31 males and 18 females) were delivered from a local farmer on the day of the experiments. They were premedicated with azaperone (4 mglkg i.m.), cannulated in a peripheral ear vein, and given metomidate until adequate anesthesia was achieved (4-10 mgikg i.v.). Additional metomidate (4 mgikg) was given when necessary. After local lidocaine injection tracheotomy was performed with a 3.0-3.5-mm cuffed Sheridan endotracheal tube, depending on tracheal size. The tube was connected via a small humidifier (Portex Termovent 600) to a Servo 900 B ventilator (ElemaScheinander, Stockholm, Sweden). The pigs were mechanically ventilated throughout the operation at 40 breathstmin. Tidal volume was adjusted when necessary to maintain arterial Pco, at 4.6-5.9 kPa. A small Foley urine catheter (Silastic Foley, 2.7 mml8Ch.3 mL, Dow Corning SA, Valbonne, France) was inserted through the tracheostomy, directed rostral, and placed in the subglottal space. The piglets remained on the respirator for 60 min after surgery, after which at least 30 min of spontaneous respiration was necessary, to attain stable respiratory conditions. The respiratory rate, minute volume, and tidal volume were monitored continuously for the rest of the experiment with a Bear NVM-I Neonatal Volume Monitor (Bear Medical Systems Inc., Riverside CA) and with a TOA EPR-131-A electronic polyrecorder (Semitronic AIS, Japan). The rectal temperature was monitored continuously and maintained at 38.0-39S°C by means of a heating blanket and when necessary a heating lamp. A catheter was inserted into a superficial artery on the inside of the hind leg and connected to a strain gauge transducer, so that the mean arterial blood pressure could be recorded continuously by a Gould recorder 2600s (Gould Inc. Recording Systems, Cleveland, OH). The pulse was monitored continuously via skin electrodes. A urinary catheter was placed in the bladder through a midline suprapubic laparotomy. Through the ear vein a solution containing 0.7% NaCl was administered at a rate of 10 mL/kgih. Blood glucose was measured with a reflectometer (Hypocount MX B, Boehringer, Mannheim, FGR). A lumbar puncture needle was inserted i.c.m., and about 6 droplets of CSF were withdrawn before 200 p L of water or various concentrations of P-endorphin were injected. After this the respiratory and cardiovascular patterns were recorded and/or the laryngeal chemoreflex was induced.
In this study a period of apnea was defined as the respiratory response to insufflation of the larynx with ammonia-saturated air. Several small pieces of gauze soaked in 6 mL of ammonia (10.8 M, Prolabo ammonia solution, minimum 20%, density 0.92 analytical reagent; Paris, France) were placed in a 50-mL syringe, and 23 mL of ammonia-saturated air were injected. The piglets were killed with pentobarbital at the end of the trial.
Experimentalprotocol. As a pilot experiment 1 mg (n = I), 0.5 mg (n = I), 0.1 mg (n = 7), and 0.01 mg (n = 1) of P-endorphin or water (n = 2) were injected i.c.m., and the respiratory and cardiovascular patterns were recorded.
Based on these initial experiments, 0.1 mg of 0-endorphin i.c.m. was found to be the lowest dose inducing respiratory pauses accompanied by blood pressure increases and reductions in heart rate. We therefore decided to inject 0.1 or 0.2 mg of P-endorphin i.c.m. before we induced the laryngeal chemoreflex. Piglets were randomized to laryngeal chemoreflex- Piglets with Pao, < 9.0 kPa, Paco, > 5.5 kPa, or base excess > -6 mmol/L (n = 7) were given water i.c.m. and one period of apnea. These piglets were used together with the randomized piglets which were pretreated with water i.c.m. before the laryngeal chemoreflex (n = 6), for relating increase in blood pressure, decrease in heart rate, and apnea duration. In these piglets (n = 13) we also compared the blood gases and the respiratory minute volume before and after each apnea.
Blood samples. Arterial blood samples were taken throughout the trial and before and 5 min after each period of apnea. Temperature-corrected blood gases were measured with an AVL 945 automatic blood gas system (AVL Biomedical Instruments, Schaffhausen, Switzerland). Hb was measured with a CO-oximeter 482 (Bergman Instrumentering NS, Lexington, MA), and hematocrit with a Hematastat (model TM C-70, Separation Technology Inc., Salt Lake City, UT). The withdrawn blood was replaced with an equal volume of sterile NaCl (0.9%), and the catheter was flushed with heparinized saline (4 UImL).
Sampling of vitreous humor. The vitreous humor was collected from the piglets immediately (within 5 min) after death. The conjunctiva was dissected free from the sclera. Vitreous humor was sampled with a vacutainer (82 X 10.25 mm, A3274, Becton Dickinson, Vacutainer Systems Europe BP N037-3841 Meylan Cedex, France) through a puncture of the sclera about 6 mm posterior to the corneal limbus. One hundred to three hundred microliters of fluid were taken at each sampling. The samples were immediately centrifuged for 10 min at 1800 X g, 4"C, to remove cells or other contaminating particles (pigmented pieces of retina), using a Millipore Ultrafree-MC 10.000 NMWL filter unit (Millipore Products Division, Bedford, UK). The clear vitreous humor was transferred into polypropylene tubes and frozen at -20°C until analyzed.
Analysis of hypoxanthine. The hypoxanthine levels in vitreous humor were analyzed by HPLC (12) .
Statistics. The Wilcoxon signed rank test was applied for comparing matched variables. The Mann-Whitney U test was applied for comparison of two groups. The Spearman rank correlation test was used for correlation studies. Values are given as medians and ranges. The median, range, and mean 2 1 SD are given for the duration of the apnea and the hypoxanthine levels in the vitreous humor.
RESULTS
Pilot Trials &Endorphin i.c.m. Doses of 0.5 (n = 1) and 1 mg (n = 1) of P-endorphin injected i.c.m. of the piglets induced a decrease in respiratory minute volume, heart rate, and blood pressure during the first 10 min. Within the next 35 min an irregular respiratory pattern with periods of apnea accompanied by increased blood pressure and a decrease in heart rate followed and lasted 30-50 min before the piglets died (Fig. 1) .
A dose of 0.1 mg of P-endorphin injected i.c.m. of the piglets (n = 19) induced similar but less pronounced respiratory and cardiovascular changes. The piglets survived for more than 3 h. During the time of irregular respiratory and cardiovascular patterns induced by 0.1 mg of P-endorphin i.c.m., the mean respiratory minute volume decreased by 12% (p < 0.05), heart rate decreased by 9% ( p < 0.05), and the blood pressure decreased by 8% ( p < 0.01) compared with the values before the injection of P-endorphin. Arterial Po, and base excess also decreased (p < 0.01), but the Pco, was unchanged. Naloxone, 100 pg/kg i.v. in piglets (n = 6) given 5 min after the start of the P-endorphin-induced irregular respiratory and cardiovascular patterns, caused an immediate increase of 14% in the respiratory minute volume ( p < 0.05), of 11% in the heart rate (p < 0.05), and of 10% in the blood pressure ( p < 0.05). Doses of 0.01 mg of P-endorphin or water injected i.c.m. in the piglets (n = 3) induced no changes in the respiratory minute volume, heart rate, or blood pressure, within 120 min.
Based on these initial studies we decided to inject 0.1 and 0.2 mg of P-endorphin i.c.m. before we induced the laryngeal chemoreflex.
Main Trials
Age, weight, blood glucose, Hb, Izematocrit, and base excess before the laryngeal chemoreflex-induced apnea. The age, weight, blood glucose, Hb, and liematocrit showed no statistically significant differences between the groups of piglets (Table 1) Table 1) .
Duration of the laryngeal chemoreflex-induced apnea. The laryngeal chemoreflex response consists of apnea, blood pressure increase, and decrease in heart rate (Fig. 2) . Doses of 0.1 mg (n = 6) and 0.2 mg (n = 6) of P-endorphin were injected i.c.m., and the apnea was induced 5 rnin after the irregular respiratory and cardiovascular patterns had been obtained. The median of the periods of apnea was 29 s ((range 15-70, mean 40 + 13) for the piglets pretreated with 0.1 mg of P-endorphin, and 37 s (range 15-150, mean 43 33) for the piglets pretreated with 0.2 mg of P-endorphin. The duration of these periods of apnea did not differ significantly from those in the piglets pretreated with water i.c.m. (n = 6), which had a median of 24 s (range 15-55, mean 28 +-9) (Fig. 3) . However, two of the piglets, pretreated with P-endorphin, 0.1 and 0.2 mg, x a n 2. The respiratory and cardiovascular patterns after :a1 chemoreflex with NH,-saturated air.
10 s (range 0-30, mean 9 t 6). These periods of apnea were shorter than those in the piglets pretreated with water i.c.m. (n = 6) ( p < 0.01) (Fig. 3) . The median of the induced apnea in the piglets pretreated with 0.1 mg of P-endorphin i.c.m., followed by 100 pg/kg naloxone i.v. after the irregular respiratory and cardiovascular patterns had been obtained (n = 6), was 11 s (range 5-29, mean 13 t 8). These periods of apnea were also shorter than those in the piglets pretreated with water i.c.m. (n = 6) ( p < 0.05) (Fig. 3) .
Hypoxanthine levels in the vitreous humor after the laryngeal chemorejlex-induced apnea. The median of the hypoxanthine levels in vitreous humor in the piglets which received 0.1 mg of P-endorphin i. (range 29-47, mean 41 + 8), than the piglets pretreated with water i.c.m. (n = 6) (p < 0.05) (Fig. 4) .
CONTR. END END X 2 NAL END N
Blood gases and the respiratory minute volume before and after the laryngeal chemoreflex-induced apnea. In the piglets pretreated with water i.c.m. (n = 13) only, the Po, was decreased from a median of 9.5 kPa before the laryngeal chemoreflex-induced apnea to 8.5 kPa 5 min after the periods of induced apnea ( p < 0.05). The Pco,, base excess, and minute volume were unchanged.
The duration of the laryngeal chemoreflex-induced apnea related to the increase in blood pressure and the decrease in heart rate. In the piglets pretreated with water i.c.m. (n = 13), the duration of the apnea was correlated with the increase in blood pressure, r = 0.87 (p < 0.01). The duration of the apnea was not related to the drop in heart rate, r = 0.4 ( p = 0.19).
Increase in blood pressure related to the decrease in heart rate during the laryngeal chemoreflex. During the apnea, the increase in blood pressure was not related to the decrease in heart rate during the induced apnea in the piglets (n = 13), r = 0.4 ( p = 0.13).
DISCUSSION
The main finding in this study was that naloxone reduced the duration of laryngeal chemoreflex-induced apnea. This reflex consists of prolonged expiration, an increase in blood pressure, and a decreased heart rate. Furthermore, 0.1-1 mg of P-endorphin i.c.m. caused a decrease in respiratory minute volume, heart rate, and blood pressure within 15 min. Within 45 min respiratory pauses developed with accompanying blood pressure increases and decreases in the heart rate ( Fig. I) , similar to the respiratory and cardiovascular pattern of the induced laryngeal chemoreflex (Fig. 2) .
Interestingly, P-endorphin has been found to increase the expiratory phase of the tidal volume (13) and naloxone to shorten the Heuring Breuer reflex (14) .
The respiratory pattern in piglets induced by P-endorphin seems to contain a mechanism different from that of adult dogs (13) . The respiratory pattern may be due to activation of p-receptors situated at different anatomical sites after diffusion of P-endorphin. Superficial activation of receptors on the dorsal pons induced a decreased tidal volume and decreased sensitivity to CO,. Activation of the superficial receptors of the ventral medulla induced a decreased tidal volume, decreased respiratory rate, and decreased sensitivity to CO,, and activation of receptors in the ambiguous nucleus induced a decrease increase is lower after hyperoxia (decreased stimulation of arterial chemoreceptors) and after a-aclrenergic blockade during the laryngeal chemoreflex (17) . During the laryngeal chemoreflex, blood from the kidneys, intestines, and lower/upper extremities is redistributed to the brain and bronchioles. This redistribution of blood is also counteracted by a-adrenergic blockade (17) . Because p-agonists release catecholamines in plasma, the blood pressure increase and the blood flow redistribution during the laryngeal chemoreflex may be partly due to release of norepinephrine caused by a p-agonist.
The decrease in heart rate during the laryngeal chemoreflex is significantly reduced after hyperoxia and after a parasympathetic blockade (17) . The blood pressure increase and heart rate decrease during laryngeal chemoreflex are also influenced by stimuli from the lung-inflating receptors (17) .
Furthermore, neither hyperoxia, nor a-or P-adrenergic blockades influence the duration of the apnea during this reflex (17) . Atropine, however, does decrease the duration (18) . Because 0-endorphin levels in the CSF after the laryngeal chemoreflex-induced apnea correlated significantly with the duration of the apnea (9) , and because naloxone decreases respiratory depression during this reflex, the laryngeal chemoreflex-induced apnea in piglets may partly be due to stimulation of p-receptors. Also the respiratory and cardiovascular patterns seen after injection of 0.1-1-mg doses of P-endorphin i.c.m., which are similar to those in laryngeal chemoreflex, may indicate an activation of p-receptors.
Interestingly, vagotomy sustains the vasomotor effect but eliminates the respiratory and heart rate depression to P-endorphin injected i.c.m. (13) . Moreover, 0.1 and 0.2 mg of P-endorphin i.c.m. did not significantly prolong the duration of the apnea during the laryngeal chemoreflex. This may be because the apnea stimulus induced enough 0-endorphin release to saturate the p-receptors (9), or because P-endorphin did not reach the nuclei involved in the reflex. A third possibility is that higher doses of opiates would have prolonged the apnea. It is concluded that 0-endorphin is involved in the induction of the apnea during laryngeal chemoreflex, possibly by activating p-receptors.
